The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial.
View/ Open
Date
2018-04-01Author
Wilson, JM
Dearnaley, DP
Syndikus, I
Khoo, V
Birtle, A
Bloomfield, D
Choudhury, A
Graham, J
Ferguson, C
Malik, Z
Money-Kyrle, J
O'Sullivan, JM
Panades, M
Parker, C
Rimmer, Y
Scrase, C
Staffurth, J
Stockdale, A
Cruickshank, C
Griffin, C
Hall, E
CHHiP Investigators,
Type
Journal Article
Metadata
Show full item recordAbstract
PURPOSE: Outcome data on radiation therapy for prostate cancer in an elderly population are sparse. The CHHiP (Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy in Prostate Cancer) trial provides a large, prospectively collected, contemporary dataset in which to explore outcomes by age. METHODS AND MATERIALS: CHHiP participants received 3 to 6 months of androgen deprivation therapy and were randomly assigned (1:1:1) to receive 74 Gy in 37 fractions (conventional fractionation), 60 Gy in 20 fractions, or 57 Gy in 19 fractions. Toxicity was assessed using clinician-reported outcome (CRO) and patient-reported outcome questionnaires. Participants were categorized as aged < 75 years or ≥ 75 years. Outcomes were compared by age group. RESULTS: Of 3216 patients, 491 (15%) were aged ≥ 75 years. There was no difference in biochemical or clinical failure rates between the groups aged < 75 years and ≥ 75 years for any of the fractionation schedules. In the group aged ≥ 75 years, biochemical or clinical failure-free rates favored hypofractionation, and at 5 years, they were 84.7% for 74 Gy, 91% for 60 Gy, and 87.7% for 57 Gy. The incidence of CRO (grade 3) acute bowel toxicity was 2% in both age groups. The incidence of grade 3 acute bladder toxicity was 8% in patients aged < 75 years and 7% in those aged ≥ 75 years. The 5-year cumulative incidence of CRO grade ≥ 2 late bowel side effects was similar in both age groups. However, in the group aged ≥ 75 years, there was a suggestion of a higher cumulative incidence of bowel bother (small or greater) with 60 Gy compared with 74 Gy and 57 Gy. Patient-reported bladder bother was slightly higher in the group aged ≥ 75 years than the group aged < 75 years, and there was a suggestion of a lower cumulative incidence of bladder bother with 57 Gy compared with 74 Gy and 60 Gy in patients aged ≥ 75 years, which was not evident in those aged < 75 years. CONCLUSIONS: Hypofractionated radiation therapy appears to be well tolerated and effective in men aged ≥ 75 years. The 57-Gy schedule has potential advantages in that it may moderate long-term side effects without compromising treatment efficacy in this group.
Collections
Subject
CHHiP Investigators
Intestines
Humans
Prostatic Neoplasms
Radiation Injuries
Androgen Antagonists
Incidence
Prospective Studies
Age Factors
Aged
Middle Aged
Male
Radiotherapy, Intensity-Modulated
Urinary Bladder
Radiation Dose Hypofractionation
Research team
Clinical Trials & Statistics Unit
ICR-CTSU Urology and Head and Neck Trials Team
Clinical Academic Radiotherapy (Dearnaley)
Language
eng
Date accepted
2018-01-03
License start date
2018-04
Citation
International journal of radiation oncology, biology, physics, 2018, 100 (5), pp. 1179 - 1189
Publisher
ELSEVIER SCIENCE INC